IXICO Announces Two New Alzheimer's Disease Contracts Valued at £1.5 Million

IXICO plc has secured two new contracts in the Alzheimer's disease sector, valued at approximately £1.5 million. The contracts include a Phase 2b clinical trial with a biotechnology company and an extension with an existing client for a blood-based biomarker. Revenue from these contracts is anticipated to be recognized over the next one to three years, contributing to the company's strengthened order book following a recent report of 28% revenue growth for the 2026 fiscal year.